"On May 21, 2015, the House Energy and Commerce Committee unanimously ordered to be reported H.R. 6, the 21st Century Cures Act. On July 2, 2015, the House Committee on Rules published a committee print of H.R. 6. On July 7, 2015, H.R. 6 was reported by the Committee on Energy and Commerce, and the House Committee on Ways and Means was discharged from further consideration of the bill. The bill would reauthorize the National Institutes of Health (NIH) through FY2018 and provide other funding to the agency through FY2020. In addition, the bill would promote and encourage more strategic planning for research conducted by NIH; change loan support for young, emerging scientists; promote pediatric research; and encourage more collaborative research activities. The bill also focuses on changes to the Food and Drug Administration's (FDA's) regulatory procedures for drugs and devices by requiring the issuance of more guidance and increasing regulatory flexibility in areas such as precision (or personalized) medicine, types of data that could serve as evidence of safety and effectiveness, antibiotic drug development, orphan drugs, and medical devices. The bill proposes additional funding for the FDA to support some of its efforts in certain specified areas. […] This report provides a brief summary of each provision of H.R. 6 as published by the Rules Committee on July 2, 2015. Each summary includes a brief description of current law and an explanation of how the bill would change current law."
CRS Report for Congress, R44071
Federation of American Scientists: http://www.fas.org/sgp/crs/index.html